An investigational oral selective orexin receptor 2 agonist significantly improved measures of wakefulness, sleepiness, and cataplexy in adults with narcolepsy type 1.
An investigational oral selective orexin receptor 2 agonist demonstrated significantly improved measures of wakefulness, sleepiness, and cataplexy in a phase 2b study of adults with narcolepsy type 1 .
NT1 is a chronic disorder caused by loss of orexin neurons, resulting in low orexin levels in the brain. Hallmarks of the disorder include excessive daytime sleepiness, cataplexy, disrupted nighttime sleep, and sleep paralysis, leading to reduced quality of life. Current treatments primarily aim to improve wakefulness and control cataplexy but do not address the underlying pathophysiology. Oveporexton is designed to directly address the orexin deficiency in NT1 by selectively stimulating the orexin receptor 2. “These data suggest that restoring orexin signaling has the potential to help people with narcolepsy type 1 achieve near normal ranges of wakefulness as seen in healthy individuals while also positively impacting the broader spectrum of the disease,” co-investigator Sarah Sheikh, MD, MSc, BM BCh, head of the Neuroscience Therapeutic Area Unit and Global Development at Takeda, toldResults of the phase 2b results, with first author Yves Dauvilliers, MD, with the Sleep and Wake Disorders Center, Department of Neurology, Gui de Chauliac Hospital, Montpellier, France, wereconfirmed via polysomnography and multiple sleep latency testing. Participants had baseline Epworth Sleepiness Scale total score >12 and four or more episodes of cataplexy per week during screening. Participants received either once- or twice-daily oveporexton at doses of 0.5 mg, 2 mg, 2 mg titrated to 5 mg, 7 mg once daily, or matching placebo for 8 weeks. The primary outcome was the change from baseline to week 8 in average sleep latency on the Maintenance of Wakefulness Test . Secondary endpoints included changes from baseline to week 8 in the ESS total score, weekly cataplexy rate, and the occurrence of adverse events. Across oveporexton doses, average sleep latency on the MWT increased from 3.6 to 5.6 minutes at baseline to 16.5 to 30.7 minutes at week 8 compared with a change from 6.1 minutes at baseline to 4.7 minutes at week 8 with placebo. Oveporexton led to dose-dependent improvements of nearly 14-27 minutes in average sleep latency — “markedly greater than mean improvements of 2-12 minutes observed with currently available narcolepsy medications,” the investigators reported. At 8 weeks, 37%-81% of oveporexton-treated patients had an average sleep latency of 20 minutes or more, on par with healthy individuals, they noted. Improvements in ESS total scores were also greater than those observed with currently available narcolepsy medications, with 79% of participants who received oveporexton having scores at or below the normative threshold of 10 points at week 8. Mean ESS total scores decreased from 18 to 19 at baseline to 4.8 to 8.9 at week 8 compared with a change from 18.6 at baseline to 16.0 at week 8 with placebo. The average weekly cataplexy rate decreased from about 15 to 31 episodes at baseline to 2 to 10 episodes at week 8 compared with 23 episodes at baseline to 9 episodes at week 8 with placebo. Decreases in cataplexy frequency were observed with all oveporexton doses, reaching significance with the 2 mg twice daily dose and the 2 mg followed by 5 mg daily dose, as compared with placebo at week 8 for the treatment of excessive daytime sleepiness in NT1. Global phase 3 trials of oveporexton are currently underway., Thomas Scammell, MD, professor of neurology, Harvard Medical School, Boston, said the fact that performance on the wakefulness test was “well into the normal range” with oveporexton is “pretty impressive and something that we very infrequently see with current medicines.” Likewise, ESS scores “shifted into normative ranges” with oveporexton. By contrast, “existing narcolepsy medications still leave many symptomatic,” said Scammell, who wasn’t involved in the study.I take care of a lot of narcolepsy patients, and we have a variety of medications. On average, they are pretty good, but there’s definitely room for improvement, so this could be a real game changer,” he said. Scammell noted that a number of companies are developing orexin agonists. “It’s quite likely that a few years from now, when these drugs are clinically available, we’re going to see a shift from some of our currently use drugs towards this new class of drugs for narcolepsy,” he said., Andrew Spector, MD, professor of neurology, Duke University School of Medicine, Durham, North Carolina said, “Orexin agonists are an entirely novel way to treat narcolepsy type 1. We currently have no equivalent options.” “Like levodopa for Parkinson’s disease, orexin agonists can specifically compensate for the lack of orexin that defines this disease. All existing drugs for narcolepsy use alternative neurotransmitter pathways to circumvent the missing orexin. The prospect of adding an additional treatment option for this patient population is exciting,” said Spector, who wasn’t involved in the study. This study was supported by Takeda. Several authors have disclosed relationships with Takeda. Scammell has consulted for and received research grants from Takeda. Spector had no relevant disclosures.All material on this website is protected by copyright, Copyright © 1994-2025 by WebMD LLC. This website also contains material copyrighted by 3rd parties.
Abnormal Sleep Pattern Sleep Disorder Somnipathy Narcolepsy Cataplexy Sleep Select Sleep Disorders Idiopathic Hypersomnia Excessive Daytime Sleepiness Receptors Patient Safety Adverse Effects Side Effects Grant Parkinson's Disease Parkinson Disease Parkinsons Parkinson Parkinson Disease (PD) Quality Of Life QOL Health Related Quality Of Life
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
NBA Admits Grizzlies Robbed of Potential Game-Winning Possession in Loss to WarriorsOfficials got a crucial call wrong in the closing seconds.
Read more »
Existing drug has potential for immune paralysisWhen the immune system does not function properly, individuals become more susceptible to infections caused by viruses, bacteria, or fungi. Researchers have demonstrated that an existing drug can revive immune cells that are not functioning correctly.
Read more »
Michigan QB Bryce Underwood displays growing pains, potential in spring gameAll eyes were on Michigan QB Bryce Underwood, who will compete for playing time ahead of the season, during the Wolverines' spring game.
Read more »
Unexpected Season 7: Latest News, Potential Release Date, Potential Cast, & Everything We KnowUnexpected season 6 cast posing with family and with a baby bump
Read more »
Xbox Game Pass Users Say New Day One Game Is “Game of the Year”Xbox Game Pass Ultimate subscribers are claiming the latest day one game added this week is the Game of the Year.
Read more »
Every Game Coming To Xbox Game Pass (& Every Game Leaving) In May 2025DOOM Guy from DOOM: The Dark Ages with characters from Modern Warfare 2 and Dredge on either side.
Read more »